Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 911-917

  Masuda, Hiroko ^a,b   Masuda, Norikazu ^a   Kodama, Yoshinori ^a   Ogawa, Masami ^a   Karita, Michiko ^a   Yamamura, Jun ^a   Tsukuda, Kazunori ^b   Doihara, Hiroyoshi ^b   Miyoshi, Shinichiro ^b   Mano, Masayuki ^a   Nakamori, Shoji ^a   Tsujinaka, Toshimasa ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Basal like phenotype; Ki 67; Neoadjuvant chemotherapy; Pathological complete response; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; HUMAN TISSUE; JAPAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79954434628     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1371-4     Document Type: Article

References (26)

1. SJ Dawson E Provenzano C Caldas 2009 Triple negative breast cancers: clinical and prognostic implications Eur J Cancer 45 Suppl 1 27 40 19775602 10.1016/S0959-8049(09)70013-9
2. EA Rakha ME El-Sayed AR Green, et al. 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D (Pubitemid 46120191)
3. Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65
4. N Kuroda M Ohara K Inoue, et al. 2009 The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma Med Mol Morphol 42 128 131 19536621 10.1007/s00795-008-0428-5 1:CAS:528:DC%2BD1MXntlOgsbo%3D
5. S Pintens P Neven M Drijkoningen, et al. 2009 Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 J Clin Pathol 62 624 628 19561231 10.1136/jcp.2008.061358 1:STN:280:DC%2BD1MvkvF2msA%3D%3D
6. EA Rakha SE Elsheikh MA Aleskandarany, et al. 2009 Triple negative Breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res 15 2301 2310 10.1158/1078-0432.CCR-08-2132
7. O Gluz C Liedtke N Gottschalk, et al. 2009 Triple-negative breast cancer-current status and future directions Ann Oncol 20 1913 1927 19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
8. B Fisher J Bryant N Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 9704717 1:CAS:528:DyaK1cXlsFCgurg%3D (Pubitemid 28363030)
9. SM Scholl A Fourquet B Asselain, et al. 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial:S6 Eur J Cancer 30A 645 652 8080680 10.1016/0959-8049(94)90537-1 1:STN:280: DyaK2czmtFyltw%3D%3D (Pubitemid 24164252)
10. C Liedtke C Mazouni KR Hess, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 18250347 10.1200/JCO.2007.14.4147
11. LA Carey EC Dees L Sawyer, et al. 2007 The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D (Pubitemid 46698581)
12. SC Abrial F Penault-Llorca R Delva, et al. 2005 High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer Breast Cancer Res Treat 94 255 263 16267618 10.1007/s10549-005-9008-8 (Pubitemid 41677630)
13. von Minckwitz G, Sinn HP, Raab G et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30
14. Hai E OgawaY K Matsumoto, et al. 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int J Clin Oncol 13 431 435 10.1007/s10147-008-0770-6
15. EM Berns JA Foekens R Vossen, et al. 2000 Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60 2155 2162 10786679 1:CAS:528:DC%2BD3cXivVaksb4%3D (Pubitemid 30225178)
16. L Assersohn J Salter TJ Powles, et al. 2003 Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer Breast Cancer Res Treat 82 113 123 14692655 10.1023/B:BREA. 0000003968.45511.3f 1:STN:280:DC%2BD3sngvFCqtA%3D%3D (Pubitemid 37476011)
17. RJ Burcombe A Makris PI Richman, et al. 2005 Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155 15611798 10.1038/sj.bjc. 6602256 1:CAS:528:DC%2BD2MXhtFSjsr0%3D (Pubitemid 40188448)
18. JM Harvey GM Clark K Osborne, et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
19. A Goldhirsh JH Glick RD Gelber, et al. 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326 (Pubitemid 41511089)
20. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
21. A Goldhirsch JN Ingle RD Gelber, et al. 2009 Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer Ann Oncol 20 1319 1329 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D
22. AC Wolff MEH Hammond JN Schwartz, et al. 2007 American society of clinical oncology/College of American pathologists guideline recommendations of human epidermal growth factor receptors 2 testing in breast cancer J Clin Oncol 25 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
23. Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing and estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 (Epub)
24. SK Pal J Mortimer 2009 Triple-negative breast cancer: novel therapies and new directions Maturitas 63 269 274 19632796 10.1016/j.maturitas.2009.06.010 1:CAS:528:DC%2BD1MXpsF2itrs%3D
25. B Corkery J Crown M Clynes, et al. 2009 Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann Oncol 20 862 867 19150933 10.1093/annonc/mdn710 1:STN:280:DC%2BD1MzgvVyitw%3D%3D
26. Inbar-Rozensal D, Castiel A, Visochek L et al (2009) A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer res 11:R78